Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.74 |
| ▸ | HPGD | P15428 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.52 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.51 |
| ▸ | APEX1 | P27695 | 1/20 | 0.51 |
| ▸ | CDC7 | O00311 | 1/20 | 0.51 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21788558 | 0.84 | KMT2A (0.55) | HTTSMN1; SMN2HPGDLMNAALDH1A1 | |
| SCHEMBL5132693 | 0.73 | LMNA (0.74) | HTTSMN1; SMN2HPGDLMNAALDH1A1 | |
| SCHEMBL3250370 | 0.71 | LMNA (0.71) | HTTSMN1; SMN2HPGDLMNAALDH1A1 | |
| SCHEMBL17574490 | 0.70 | LMNA (0.59) | HTTSMN1; SMN2HPGDLMNAALDH1A1 | |
| SCHEMBL1859610 | 0.69 | ALDH1A1 (0.64) | HTTSMN1; SMN2HPGDLMNAALDH1A1 | |
| SCHEMBL12604487 | 0.69 | NPC1 (0.73) | HTTSMN1; SMN2HPGDLMNAALDH1A1 | |
| SCHEMBL2372185 | 0.69 | PI4KA (0.61) | HTTSMN1; SMN2HPGDLMNAALDH1A1 | |
| SCHEMBL17060218 | 0.69 | NUDT1 (1.00) | HTTSMN1; SMN2HPGDLMNAALDH1A1 | |
| SCHEMBL1861839 | 0.69 | ERBB2 (1.00) | HTTSMN1; SMN2HPGDLMNAALDH1A1 | |
| SCHEMBL29805612 | 0.68 | CDC7 (1.00) | HTTHPGDLMNAALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118726352-A | Promoter element and application thereof in biosynthesis of 3-hydroxy propionic acid | 山东大学 | 2024-10-01 | — | — | CN | claimed |
| CN-118726352-A | Promoter element and application thereof in biosynthesis of 3-hydroxy propionic acid | 山东大学 | 2024-10-01 | — | — | CN | disclosed |
| CN-111880837-B | Business process engine system supporting dynamic expansion and visual configuration | 上海伯俊软件科技有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-114981415-B | Systems and methods for enhanced immunotherapy | 杭州启函生物科技有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20230338528-A1 | SYSTEMS AND METHODS FOR ENHANCED IMMUNOTHERAPIES | HANGZHOU QIHAN BIOTECHNOLOGY CO. LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| EP-4240830-A1 | SYSTEMS AND METHODS FOR ENHANCED IMMUNOTHERAPIES | Hangzhou Qihan Biotechnology Co., Ltd. (CN) | 2023-09-13 | — | — | EP | disclosed |
| WO-2023078287-A1 | SYSTEMS AND METHODS FOR ENHANCED IMMUNOTHERAPIES | HANGZHOU QIHAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-05-11 | — | — | WO | disclosed |
| US-20220281998-A1 | BIFIDOBACTERIUM SPP. EXPRESSING AND SECRETING DIABODY-TYPE BSAB | AZUSAPHARMA SCIENCES, INC. | 2022-09-08 | — | — | US | disclosed |
| CN-114981415-A | Systems and methods for enhanced immunotherapy | 杭州启函生物科技有限公司 | 2022-08-30 | — | — | CN | disclosed |
| WO-2022095902-A1 | SYSTEMS AND METHODS FOR ENHANCED IMMUNOTHERAPIES | HANGZHOU QIHAN BIOTECHNOLOGY CO., LTD. (CN) | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281998-A1 | BIFIDOBACTERIUM SPP. EXPRESSING AND SECRETING DIABODY-TYPE BSAB | CD2, CD22, CD4 | HTT 3588/4885SMN1; SMN2 2619/4885HPGD 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.